55243-15-7

Basic information

• Product Name: Ethyl 2-aMino-2-(2-pyridinyl)acetate
• Synonyms: Ethyl 2-aMino-2-(2-pyridinyl)acetate;Ethyl 2-(2-pyridinyl)-DL-glycinate;AMINO-PYRIDIN-2-YL-ACETIC ACID ETHYL ESTER;2-Pyridineacetic acid, a-aMino-, ethyl ester;Ethyl 2-amino-2-(pyridin-2-yl)acetate;Ethyl 2-amino-2-(pyridin-2-yl)
• CAS NO: 55243-15-7
• Molecular Formula: C₉H₁₂N₂O₂
• Molecular Weight: 180.21
• Mol File: 55243-15-7.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Storage Temp.: Keep in dark place,Sealed in dry,Store in freezer, under -20°C
• CAS DataBase Reference: Ethyl 2-aMino-2-(2-pyridinyl)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 2-aMino-2-(2-pyridinyl)acetate(55243-15-7)
• EPA Substance Registry System: Ethyl 2-aMino-2-(2-pyridinyl)acetate(55243-15-7)

Safety Data

• Hazardous Substances Data: 55243-15-7(Hazardous Substances Data)

Usage

General Description

Ethyl 2-amino-2-(2-pyridinyl)acetate, also known as ethyl 2-(2-pyridyl)glycinate, is a chemical compound with the molecular formula C9H11NO2. It is a derivative of glycine and is commonly used as a building block in the synthesis of pharmaceuticals and agrochemicals. Ethyl 2-aMino-2-(2-pyridinyl)acetate has the potential to act as a ligand in coordination chemistry and can also be used as a chiral auxiliary in asymmetric synthesis. Additionally, ethyl 2-amino-2-(2-pyridinyl)acetate has been studied for its potential anticonvulsant and neuroprotective properties, making it of interest in the field of medicinal chemistry. Overall, this compound has diverse applications and potential pharmacological properties that make it an important chemical in various industries.

Upstream product

• 2739-98-2 ethyl 2-(pyridinyl-2)acetate 
• 71721-67-0 ethyl 2-hydroxyimino-2-(pyridin-2-yl)acetate 

Downstream Products

• 119448-87-2 ethyl imidazo[1,5-a]pyridine-1-carboxylate 
• 138891-51-7 imidazo<1,5-a>pyridine-1-carboxylic acid 
• 138891-58-4 ethyl 3-bromoimidazo[1,5-a]pyridine-1-carboxylate 
• 1011527-99-3 ethyl {[(2-fluorophenyl)acetyl]amino}(pyridin-2-yl)acetate 
• 1011528-01-0 ethyl 3-(2-fluorobenzyl)imidazo[1,5-a]pyridine-1-carboxylate 
• 1011528-15-6 3-(2-fluorobenzyl)imidazo[1,5-a]pyridine-1-carboxamide 
• 1011528-16-7 3-(2-fluorobenzyl)imidazo[1,5-a]pyridine-1-carbonitrile 
• 1344670-01-4 C₁₅H₁₄FN₅ 
• 1344669-74-4 C₁₇H₁₁F₄N₅ 
• 1430074-74-0 ethyl 3-phenylimidazo[1,5-α]pyridine-1-carboxylate 
• 1430074-80-8 ethyl 3-(4-(trifluoromethyl)phenyl)imidazo[1,5-α]pyridine-1-carboxylate 
• 1430074-84-2 ethyl 3-(4-methoxyphenyl)imidazo[1,5-α]pyridine-1-carboxylate 
• 924646-16-2 3-phenylimidazo[1,5-a]pyridine-1-carboxylic acid 
• 1451194-92-5 C₁₅H₉F₃N₂O₂ 

Relevant articles and documents

Synthesis and biological evaluation of imidazopyridinyl-1,3,4-oxadiazole conjugates as apoptosis inducers and topoisomerase IIα inhibitors

A series of imidazopyridinyl-1,3,4-oxadiazole conjugates were synthesized and investigated for their cytotoxic activity and some compounds showed promising cytotoxic activity. Compound 8q (NSC: 763639) exhibited notable growth inhibition that satisfies th

Synthesis and SAR of Imidazo[1,5-a[pyridine derivatives as 5-HT4 receptor partial agonists for the treatment of cognitive disorders associated with Alzheimer's disease

Alzheimer's disease (AD) is a neurodegenerative disease which has a higher prevalence and incidence in older people. The need for improved AD therapies is unmet. The 5-hydroxytryptamine4 receptor (5-HT4R) partial agonists may be of benefit for both the symptomatic and disease-modifying treatment of cognitive disorders associated with AD. Herein, we report the design, synthesis and SAR of imidazo[1,5-a] pyridine derivatives as 5-HT4R partial agonists. The focused SAR, optimization of ADME properties resulted the discovery of compound 5a as potent, selective, brain penetrant 5-HT4 partial agonist as a lead compound with good ADME properties and efficacy in both symptomatic and disease modifying animal models of cognition.

Acidic triazoles as soluble guanylate cyclase stimulators

A series of acidic triazoles with activity as soluble guanylate cyclase stimulators is described. Incorporation of the CF3 triazole improved the overall physicochemical and drug-like properties of the molecule and is exemplified by compound 25.